Literature DB >> 16386994

Amblyopia: diagnostic and therapeutic options.

Carolyn Wu1, David G Hunter.   

Abstract

PURPOSE: To provide an overview of the current state of knowledge of amblyopia and highlight recent advances in diagnosis and treatment.
DESIGN: Review of literature and perspective.
METHODS: MEDLINE search for amblyopia, with a review of all recent literature adding authors' personal perspectives on the findings.
RESULTS: Increased awareness of amblyopia and better screening techniques are required to identify children who are at risk for amblyopia at a younger age. Randomized, controlled trials have established atropine penalization as a viable alternative to occlusion therapy, have suggested that less treatment may be better tolerated and as effective as more traditionally used dosages, and have found no compelling evidence that treatment is beneficial clinically for older (over age 10) children with amblyopia.
CONCLUSION: Early detection and treatment of amblyopia can improve the chances for a successful visual outcome. Considering that the conditions that place a patient at risk for amblyopia can be identified, that amblyopia responds to treatment, and that well-tolerated treatments for the condition are now recognized, it is not unreasonable to imagine that, in the near future, severe amblyopia could be eliminated as a public health problem.

Entities:  

Mesh:

Year:  2006        PMID: 16386994     DOI: 10.1016/j.ajo.2005.07.060

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  41 in total

1.  The effect of anisometropic amblyopia on retrobulbar blood flow parameters. Anisometropic amblyopia and retrobulbar blood flow.

Authors:  Turgut Yılmaz; Mete Güler; Peykan Turkcuoglu; Hakan Artas; Gulsen Ulku; Osman Arslanhan; Mehmet Yiğit
Journal:  Int Ophthalmol       Date:  2012-05-03       Impact factor: 2.031

2.  Ocular aberrations in amblyopic children.

Authors:  Hind Ibrahem Aldebasi; Samah Mahmoud Fawzy; Ahmad A Alsaleh
Journal:  Saudi J Ophthalmol       Date:  2013-07-15

3.  An action video game for the treatment of amblyopia in children: A feasibility study.

Authors:  Christina Gambacorta; Mor Nahum; Indu Vedamurthy; Jessica Bayliss; Josh Jordan; Daphne Bavelier; Dennis M Levi
Journal:  Vision Res       Date:  2018-05-12       Impact factor: 1.886

4.  The prevalence of amblyopia in Germany: data from the prospective, population-based Gutenberg Health Study.

Authors:  Heike M Elflein; Susanne Fresenius; Julia Lamparter; Susanne Pitz; Norbert Pfeiffer; Harald Binder; Philipp Wild; Alireza Mirshahi
Journal:  Dtsch Arztebl Int       Date:  2015-05-08       Impact factor: 5.594

5.  Conventional occlusion versus pharmacologic penalization for amblyopia.

Authors:  Tianjing Li; Riaz Qureshi; Kate Taylor
Journal:  Cochrane Database Syst Rev       Date:  2019-08-28

6.  P300-based acuity estimation in imitated amblyopia.

Authors:  Marvin L Beusterien; Sven P Heinrich
Journal:  Doc Ophthalmol       Date:  2017-11-13       Impact factor: 2.379

7.  qCSF in clinical application: efficient characterization and classification of contrast sensitivity functions in amblyopia.

Authors:  Fang Hou; Chang-Bing Huang; Luis Lesmes; Li-Xia Feng; Liming Tao; Yi-Feng Zhou; Zhong-Lin Lu
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-05-19       Impact factor: 4.799

8.  A dichoptic custom-made action video game as a treatment for adult amblyopia.

Authors:  Indu Vedamurthy; Mor Nahum; Samuel J Huang; Frank Zheng; Jessica Bayliss; Daphne Bavelier; Dennis M Levi
Journal:  Vision Res       Date:  2015-04-24       Impact factor: 1.886

9.  Amblyopia therapy in Asian children: factors affecting visual outcome and parents' perception of children's attitudes towards amblyopia treatment.

Authors:  Swati Handa; Audrey Chia
Journal:  Singapore Med J       Date:  2018-11-29       Impact factor: 1.858

10.  Why is compliance with occlusion therapy for amblyopia so hard? A qualitative study.

Authors:  M Dixon-Woods; M Awan; I Gottlob
Journal:  Arch Dis Child       Date:  2006-03-10       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.